Content about Valsartan

February 8, 2013

FDA gives tentative approval to Dr. Reddy's hypertension drug

The Food and Drug Administration has given tentative approval to a generic drug for treating hypertension, according to agency records.

SILVER SPRING, Md. - The Food and Drug Administration has given tentative approval to a generic drug for treating hypertension, according to agency records.

The FDA granted tentative approval to Dr. Reddy's Labs' valsartan tablets in the 40 mg, 80 mg, 160 mg and 320 mg strengths.

The drug is a generic version of Novartis' Diovan. Various versions of the drug had sales of $1.6 billion during the 12-month period that ended in June, according to IMS Health.

January 3, 2013

Ranbaxy preserves exclusivity period for generic hypertension drug

A court has ruled in favor of Indian generic drug maker Ranbaxy Labs in a case concerning a generic blood pressure drug, the legal firm representing the drug maker said.

WASHINGTON — A court has ruled in favor of Indian generic drug maker Ranbaxy Labs in a case concerning a generic blood pressure drug, the legal firm representing the drug maker said.

Zuckerman Spaeder LLP said the U.S. District Court for the District of Columbia upheld a Food and Drug Administration decision protecting Ranbaxy's market exclusivity for a generic version of Novartis' drug Diovan (valsartan).

December 28, 2012

Mylan generic heart drug suit against FDA dismissed

A federal judge in Washington has dismissed a suit against the FDA brought up by Mylan for withholding approval for the company to sell a generic version of Novartis AG’s heart pill, Diovan.

WASHINGTON — A federal judge in Washington has dismissed a suit against the FDA brought up by Mylan for withholding approval for the company to sell a generic version of Novartis AG’s heart pill, Diovan.

U.S. District Court Judge John D. Bates said in an opinion filed on Dec. 27, that the FDA did not act “capriciously” when it denied Mylan exclusivity to market its version of Diovan. Bates also said Mylan did not show it suffered “irreparable harm” as a result.

September 24, 2012

Sandoz launches authorized generic of Diovan HCT

Generic drug maker Sandoz has launched an authorized generic version of a drug used to treat hypertension.

NEW YORK — Generic drug maker Sandoz has launched an authorized generic version of a drug used to treat hypertension.

The generics division of Swiss drug maker Novartis announced the introduction of valsartan and hydrochlorothiazide tablets, a generic version of Novartis' Diovan HCT. Novartis will continue marketing the branded version of the drug, which had sales of $2.3 billion in 2011 together with Diovan (valsartan).

September 21, 2012

FDA approves Mylan hypertension drug

The Food and Drug Administration has approved a blood pressure medication made by Mylan.

PITTSBURGH — The Food and Drug Administration has approved a blood pressure medication made by Mylan.

The drug maker announced Friday the approval of valsartan and hydrochlorothiazide tablets in the 80-mg/12.5-mg, 160-mg/12.5-mg, 160-mg/25-mg, 320-mg/12.5-mg and 320-mg/25-mg strengths.

The drug, a generic version of Novartis' Diovan HCT, is used to treat high blood pressure, or hypertension, in patients who can't control their blood pressure with one drug or who are starting therapy and need multiple drugs.

June 2, 2011

FDA: ARBs do not pose increased cancer risk

A class of drugs commonly used to control blood pressure does not increase patients’ risk of developing cancer, according to the Food and Drug Administration.

SILVER SPRING, Md. — A class of drugs commonly used to control blood pressure does not increase patients’ risk of developing cancer, according to the Food and Drug Administration.

May 12, 2011

Novartis' Diovan HCT wins HCPC’s Compliance Package of the Year award

A blood pressure drug made by Swiss drug maker Novartis has won an award from the Healthcare Compliance Packaging Council.

RICHMOND, Va. — A blood pressure drug made by Swiss drug maker Novartis has won an award from the Healthcare Compliance Packaging Council.

Novartis Diovan HCT (valsartan and hydrochlorothiazide) won the HCPC’s Compliance Package of the Year award at the council’s RxAdherence 19th annual symposium for its Shellpak packaging design, made by product packaging manufacturer MeadWestvaco Corp. Anderson Packaging, part of AmerisourceBergen Packaging Group, handles the drug’s fulfillment.

September 27, 2010

Decision Resources: Generic competition will crush hypertension drug market

The market for hypertension drugs will drop by $3 billion by the end of the...

BURLINGTON, Mass. The market for hypertension drugs will drop by $3 billion by the end of the decade due to generic competition, according to a new report by healthcare market research firm Decision Resources.

The report, announced Tuesday, found that the market for drugs to treat high blood pressure would decline from 2009’s $26 billion to $23 billion by 2019 in the United States, United Kingdom, France, Italy, Spain and Japan.

January 25, 2010

Novartis' Vasella to focus on being chairman, bows out from CEO role

Daniel Vasella will step down as CEO of Novartis to focus on his position as...